TIME AFTER TIME p e o p l e . C H E M I S T R Y . P O S S I B I L I T I E S .
12
3
9
6
AFTER TIME AFTER TIME
CHEMAGIS EXCELs IN -
·
· ·
CHEMISTRY BETWEEN
THE SCIENCE OF
PEOPLE AND ITS TRA
CHEMISTRY AND I
TRANSFORMING CHEMISTRY INTO NEW AN
AFTER TIME AFTER TIME
ANSLATION INTO LONG-TERM, TRUSTFUL RELATIONSHIPS.
TS APPLICATION IN THE PHARMACEUTICAL WORLD.
ND EXCITING
POSSIBILITIES.
AFTER TIME AFTER TIME USA Sales & Marketing Mexico Sales & Marketing
•••
ABOUT US
Founded in 1987, Chemagis Ltd. is a subsidiary of Perrigo Israel (PIL), Israel’s second largest pharmaceutical conglomerate and part of the Perrigo Group – the world’s largest manufacturer of over-thecounter pharmaceutical and nutritional products for the store-brand market. Chemagis develops, produces and markets an extensive line of high-quality Active Pharmaceutical Ingredients (API’s) and Finished Dosage Forms (FDF) for the branded and generic pharmaceutical industries. We offer our customers comprehensive, customized packages consisting of IP assets, API products, dossiers, FDF and P-IV partnerships – all complemented by strategic alliances. Chemagis combines exceptional R&D & IP capabilities with the highest manufacturing standards, including full cGMP, ICH and WHO compliance, approved by the FDA, KFDA, and certified by the Israeli Ministry of Health. Chemagis specializes in tailor-made Research and Process Development of API’s propelled by a team of experts and creative scientists, and provides solutions to meet individual requirements, regardless of complexity. Chemagis also offers complete technical and regulatory support from project inception through final production. Applying high efficiency and control measures during the entire supply, development and manufacturing chain, and throughout the product lifecycle, Chemagis provides outstanding value to hundreds of customers worldwide. Chemagis has been proactively searching for ways to preserve and improve its global leading position and recently has acquired an 85% stake in Vedant, an API manufacturing facility located approximately 30 miles
outside of Mumbai. The plant has been built to cGMP guideline compliance and is in the final stages of construction. When completed and fully operational it will produce Chemagis’ current high volume API products along with those targeted for the future. This strategic move will improve Chemagis’ operational flexibility and competitive edge. Moreover, it will increase the level of service, while maintaining our high standards of quality and customer support. The driving force behind Chemagis’ success has always been the uncompromising quality of service at every stage from advanced R&D and manufacturing procedures through worldwide marketing and long-term customer service. Chemagis has established a presence in the ethical arena, particularly in the Drug Delivery Systems market. Chemagis offers companies an innovative approach to problem solving, creativity and timeliness. Addressing both new molecular entities and marketed API’s, we provide: • Full support through the development stage • Preparation of drug master files • Assistance throughout the approval process • Full-scale production
AFTER TIME AFTER TIME
Germany Production Sales & Marketing
China Production Israel R&D Production Sales & Marketing
ChemAgis Operations
ChemAgis Markets
India Production
AFTER TIME AFTER TIME
•••
Why Us TIME AFTER TIME AFTER We take it personally ChemAgis believes in chemistry between people. We value open communication with our customers as a critical catalytic factor – improving the accuracy, efficiency and outcome of each project.
Client-focused organization Client focus means an attentive approach to project definition, continuous communication throughout development, and expert follow-up & support until final product approval.
Generic products – Specific solutions At the bottom line - our wide range of capabilities and extensive experience allows us to optimize our offering to the unique specificities of the customer and the project.
From R&D to IP A strong, multidisciplinary R&D team coupled with stateof-the-art facilities results in extraordinary development & IP capabilities.
Quality-focused organization QA is an integral part of our entire process, rather than a final step. The incorporation of QA steps early on in the development and production processes allows us to maintain consistently high quality without having to sacrifice throughput.
Take part in a true partnership In ChemAgis we believe that combining trust, flexibility and a touch of courage fosters truly beneficial partnerships. Our innovative, risk-reward approach to early patent challenges allows us and our clients to explore possibilities that would otherwise be irrelevant to both.
We invite you to challenge us … In ChemAgis we apply innovation & flexibility not only in production and R&D, but also in our business models. We invite our clients to develop new business models with us for the benefit of both parties.
•••
PRODUCT LIST
ChemAgis offers a wide range of products, with special expertise in complex, differentiated APIs. Control over all major API characteristics, including morphology, particle size, salt type, genotoxic impurity & more.
ACTIVE PHARMACEUTICAL INGREDIENTS API Name
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
Anastrozole Azacitidine Cisatracurium Besylate Cetirizine Dihydrochloride Cilostazol Donepezil Hydrochloride Exemestane Fenofibrate Flumazenil Fluticasone Propionate Gemcitabine Hydrochloride Granisetron Hydrochloride Granisetron Base Halobetasol propionate Imiquimod Lamotrigine Letrozole Levocetirizine Dihydrochloride Midazolam HCL Midazolam Maleate Midazolam Base Modafinil Mometasone Furoate Moxonidine Pentoxifylline Pramipexole Dihydrochloride Pramipexole Base Rocuronium Bromide Temozolomide Terbinafine Hydrochloride Terbinafine Base Tioconazole Tramadol Hydrochloride Zonisamide
Therapeutic Use
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
non-steroidal aromatase inhibitor anti-neoplastic, anti metabolite agent neuromuscular blocker non-sedative anti-histamine anti-thrombotic anti-alzheimer, cognition enhancer steroidal aromatase inhibitor anti-hyperlipoproteinemic benzodiazepine antagonist anti-inflammatory, anti-allergic agent anti-metabolite, anti-neoplastic anti-nauseant, anti-emetic agent anti-nauseant, anti-emetic agent anti-inflammatory immune response modifier anti-epileptic non-steroidal aromatase inhibitor non-sedative anti-histamine CNS depressant, anesthetic, sleeping aid CNS depressant, anesthetic, sleeping aid CNS depressant, anesthetic, sleeping aid anti-narcoleptic anti-inflammatory anti-hypertensive vasodilator anti-parkinsonian anti-parkinsonian neuromuscular blocker anti-neoplastic, alkylating agent anti-dermatophyte (nail fungal infection) anti-dermatophyte (nail fungal infection) anti fungal analgesic anti-epileptic
*Products under patent are not sold until patent expiration in the relevant country.
TIME AFTER TIME
AFTER TIME AFTER TIME
AFTER TIME AFTER TIME ACTIVE PHARMACEUTICAL INGREDIENTS New Products API Name
• • • • • •
Imatinib Mesylate 2,3,4 Mometasone Furoate Monohydrate 1,2 Montelukast Sodium 2,3,4 Palonosetrone Dihydrochloride 1,2,4 Rotigotine 1,2,4 R-Modafinil 2,3
Therapeutic Use
• • • • • •
anti-neoplastic agent, tyrosine kinase inhibitor anti-inflammatory prophylaxis of asthma anti-nauseant, anti-emetic agent anti Parkinson, Dopamine agonist narcolepsy & idiopathic hypersomnia
1. DMF in preparation 2. GMP material availablel 3. EDMF- AP\Technical package available 4. IP package
Products Under Development API Name
• • • • • • • • • •
Fluticasone Furoate Omeprazole Mg Rabeprazole Pantoprazole Lansoprazole Esomeprazole Omeprazole Dexlansoprazole Ambrisentan Fenofibric Acid
FINAL DOSAGE FORMS Chemagis FDFs Generic Name
• • • • • •
Anastrozole 1 mg Tablets Granisetron HCl 1, 2 mg Tablets Granisetron HCl 1, 3 mg/ml Ampoules Letrozole 2.5 mg Tablets Moxonidine 0.2, 0.3, 0.4 mg Tablets Temozolomide Capsules*
Vertical Integration FDFs (Perrigo) Generic Name
• • • • • • •
Ammonium Lactate cream, lotion Cetirizine Dihydrochloride syrup Donepezil 5, 10 mg tablets Fluticasone Propionate cream, ointment Halobetasol cream, ointment Imiquimod cream Mometasone Furoate
Therapeutic Use
• • • • • • • • • •
anti-inflammatory, anti-allergic agent proton pump inhibitor proton pump inhibitor proton pump inhibitor proton pump inhibitor proton pump inhibitor proton pump inhibitor proton pump inhibitor anti hypertensive anti-hyperlipoproteinemic
Therapeutic Use
• • • • • •
non-steroidal aromatase inhibitor anti-nauseant, anti-emetic agent anti-nauseant, anti-emetic agent non-steroidal aromatase inhibitor anti-hypertensive anti-neoplastic, alkylating agent
Therapeutic Use
• • • • • • •
moisturizer non-sedative anti-histamine anti-Alzheimer, cognition enhancer anti-inflammatory, anti-allergic agent anti-inflammatory immune response modifier anti-inflammatory
*Products under patent are not sold until patent expiration in the relevant country.
Plants
Chemagis Ltd. Headquarters 31 Lehi St., P.O.Box 2231 Bnei-Brak 51100 Israel Tel: 972-3-5773880 Fax: 972-3-5773868
Chemagis Ltd. P.O.Box 3593, Ramat Hovav Beer-Sheva 84135 Israel Tel: 972-8-6509140 Fax: 972-8-6572221
Chemagis Ltd. R&D Center 3 Hashlosha St., P.O.Box 9091 Tel Aviv 61090 Israel
Chemagis (Germany) GmbH. Kasteler Str. 45, Building D-546 D65203 Wiesbaden Germany
Chemagis USA, Inc. 115 Route 46 West, Suite D25 Mountain Lakes New Jersey 07046 U.S.A. Tel: 1-973-402-1355 Fax: 1-973-402-1388
Perrigo API (India) Plot # N 39/N 39-1, MIDC Additional Ambernath, Ambernath (East), District Thane, Maharashtra India
www.chemagis.com
Milli & Rachel 972-9-7666370
Offices